- Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial
- Full-Life Technologies Completes Construction of Belgium Manufacturing Facility and Begins Accelerator Commissioning
- Full-Life Technologies to Present Clinical and Translational Data at ESMO Congress 2026 and EANM'26 Annual Congress
- Full-Life Technologies Announces US$150 Million Financing to Accelerate Multiple Clinical Stage Assets and Manufacturing Capabilities
- Full-Life Technologies Announces Poster Presentation at AACR Annual Meeting 2026
- Full-Life Technologies' Partner SK Biopharmaceuticals Secures FDA IND Approval for Alpha-Emitter Radiopharmaceuticals Drug Candidate Accelerating Global Clinical Development
- Full-Life Technologies Announces US$77 Million Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Manufacturing Capabilities
- Full-Life Technologies to Present at the 38th Annual Congress of the European Association of Nuclear Medicine
- Full-Life Technologies to Participate in the ASCO 2025
- Full-Life Technologies Announces Appointment of Debora Barton, MD, as Chief Medical Officer
- Full-Life Technologies to Present Research on FL-031 and FL-801 at AACR 2025
- Full-Life Technologies to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
- Full-Life Technologies Announced the Progress of its Radioisotope Manufacturing Facility in Belgium
- Full-Life Technologies to Present Three Top Rated Oral Presentations at the 37th Annual Congress of the European Association of Nuclear Medicine
- Full-Life Technologies Attends the Morgan Stanley 22nd Annual Global Healthcare Conference
- Full-Life Technologies, SK Biopharmaceuticals Enter Licensing Agreement for Novel Therapeutic Targeting Multiple Solid Tumors
- Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Full-Life Technologies Disclosed Preclinical Data of its NTSR1-targeting RDC Program FL-091 in an Oral Presentation at the 2024 SNMMI Annual Meeting
- Full-Life Technologies Announces Clearance from FDA of IND Application for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Full-Life Technologies Announces Appointment of Mark S. de Jong, PhD, as Chief Technical Officer
- Full-Life Technologies will showcase preclinical data of its NTSR1-targeted RDC program FL-091 in an oral presentation at the 2024 SNMMI Annual Meeting
- Full-Life Technologies Announced the Poster Presentations of preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024
- Full-Life Technologies Achieves Regulatory Milestone with Nuclear Permit, Advancing Radioisotope Facility Construction
- Full-Life Technologies will present preclinical data of its novel PSMA-targeted RDC program 225Ac-FL-020 at the AACR Annual Meeting 2024
- Full-Life Technologies and Eckert & Ziegler Sign Actinium-225 Supply Agreement for Next Generation Radiopharmaceuticals
- Global radiotherapeutics company Full-Life Technologies announces USD $47.3 million Series B financing, Prosperity7 Ventures jointly leads the round
- Full-Life Technologies Breaks Ground for GMP Manufacturing Facility in Belgium to Advance Its End-to-end Solution for Radiopharmaceuticals
- Full-Life Technologies Announces Land Purchase in Belgium to Establish GMP Manufacturing Facility for Radiopharmaceutical Drug Production
- Full-Life Technologies Announces Appointment of Steffen Heeger, MD, PhD, as Chief Medical Officer and Fa Liu, PhD, as Chief Scientific Officer
- Full-Life Technologies to Acquire Focus-X Therapeutics, Bolstering Peptide-Focused Radiopharmaceutical Pipeline
- Full-Life Technologies Deepens Radioisotope Technology Expertise with Key Leadership Appointments and the Establishment of a Radioisotope Technology Advisory Board
- Full-Life Technologies Completes $37 Million (USD)Series A Financing to Accelerate Development of its Radiopharmaceutical Pipeline and Radiotechnology Production Platform
- Full-Life Technologies Announces Senior Executive Team Appointments
- Full-Life Technologies Launches with $10M Seed Round Financing to Advance Its Nuclear Technology & Nuclear Medicines Businesses